Clinical Trial Update: TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update comparing TA(E)C-GP to A(E)C-T in high-risk triple-negative breast cancer with validation of an mRNA-lncRNA signature; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• A(E)C-T
• TA(E)C-GP

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer, Breast Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING